A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 3045 C. to form a solution, whose concentration is controlled within 0.050.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 35 times (in volume) of that of the solvent; followed by cooling the solution down to 010 C. at a rate of 0.21 C./min; continuing to stir for 13 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.

A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 3045 C. to form a solution, whose concentration is controlled within 0.050.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 35 times (in volume) of that of the solvent; followed by cooling the solution down to 010 C. at a rate of 0.21 C./min; continuing to stir for 13 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.

The present invention relates to novel cephalosporin derivatives represented by ##STR00001##
X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

The present invention relates to novel cephalosporin derivatives represented by ##STR00001##
X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

The present invention relates to compounds that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable response. In particular, the compounds have utility in detecting the presence of a -lactamase in a sample. In addition to the compounds, methods are disclosed for analyzing a sample for the presence of a -lactmase, for example, as an indicator of expression of a nucleic acid sequence including a sequence coding for a -lactmase. Kits are disclosed that include the disclosed compounds and additional components, for example, cells, antibodies, a -lactmase or instructions for using the components in an assay.

The present invention relates to compounds that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable response. In particular, the compounds have utility in detecting the presence of a -lactamase in a sample. In addition to the compounds, methods are disclosed for analyzing a sample for the presence of a -lactmase, for example, as an indicator of expression of a nucleic acid sequence including a sequence coding for a -lactmase. Kits are disclosed that include the disclosed compounds and additional components, for example, cells, antibodies, a -lactmase or instructions for using the components in an assay.

A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 3045 C. to form a solution, whose concentration is controlled within 0.050.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 35 times (in volume) of that of the solvent; followed by cooling the solution down to 010 C. at a rate of 0.21 C./min; continuing to stir for 13 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.

A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 3045 C. to form a solution, whose concentration is controlled within 0.050.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 35 times (in volume) of that of the solvent; followed by cooling the solution down to 010 C. at a rate of 0.21 C./min; continuing to stir for 13 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.